Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 3

Acute coronary syndrome with intraventricular thrombus after using erythropoietin

Eritropoetin kullanımı sonrası intraventriküler trombüs ile birlikte akut koroner sendrom

Pages
278–279
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

KURTUL, A., DURAN, M., ÖRNEK, E., UYSAL, O. K. (2022). Acute coronary syndrome with intraventricular thrombus after using erythropoietin. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 3, 278–279. https://ajindex.com/articles/436253

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-89
  2. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007. [CrossRef] 3. Lipsic E, van der Meer P Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen, DJ, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004; 44: 473-9. [CrossRef] 4. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003;100: 11612-7. [CrossRef] 5. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004; 279: 20655-62. [CrossRef] 6. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90. [CrossRef] 7. Gladding PA, Webster MW, Kay P Late drug-eluting stent thrombosis and erythropoietin: cause and effect? Heart Lung Circ 2007; 16: 305-7. [CrossRef] 8. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, et al. REVEAL Investigators. Intravenous erythropoietin in patients with ST-segment ele- vation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011; 305: 1863-72. [CrossRef] 9. Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increa- ses the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-85
  3. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-9.